FORM PTO-1449 (REV.7-80) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY, DOCKET NO. 920010.535

APPLICATION NO. 09/088,951

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS
Martin A. Cheever and Mary L. Disis

FILING DATE
June 2, 1998

GROUP ART UNIT 1642

U.S. F	PATENT	DOCU	MENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS:	FILING DATE
Su	AA	4,205,130	05/27/80	Vihko	435	196	TI ACIAOTATE
ſ	AB	4,267,272	05/12/81	Josephson	435	7	
	AC	4,510,239	04/09/85	Miller et al.	435	7	
	AD	5,719,030	02/17/98	Kuroiwa et al.	435	7.1	
	AE_	5,738,867	04/14/98	Spitler	424	450	
	AF	5,925,362	07/20/99	Spitler et al.	424	277.1	
1	AG	5,976,546	11/02/99	Laus et al.	424	192.1	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	. :	TRANS	LATION
Su						YES	NO
	AH	CA 1 185 525	04/16/85	Canada	.:		
	ΑI	WO 95/04548	02/16/95	PCT			
V	AJ	WO 98/46769	10/22/98	PCT:			

OTHER PRIOR ART (Including Author, Title, Date. Pertinent Pages, Etc.)

Su	AK	Bakker et al., "Melanocyte Lineage-specific Antigen gp100 Is Recognized by Melanomaderived Tumor-infiltrating Lymphocytes," <i>The Journal of Experimental Medicine</i> 179:1005-1009, 1994.
	AL .	Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti- p185-HER2 Monoclonal Antibody in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer," Journal of Clinical Oncology 14(3):737-744, 1996.
	AM	Ben-Mahrez et al., "Circulating Antibodies Against C-MYC Oncogene Products In Sera Of Colorectal Cancer Patients," Int. J. Cancer 46:35-38, 1990.
	AN	Berchuck et al., "Overexpression of <i>HER-2/neu</i> Is Associated with Poor Survival in Advanced Epithelial Ovarian Cancer," <i>Cancer Research</i> 50:4087-4091, 1990.
	AO	Bernards et al., "Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector," <i>Proc. Natl. Acad. Sci. USA</i> 84:6854-6858, 1987.
	АР	Cheever et al., "Specific Adoptive Therapy Of Established Leukemia With Syngeneic Lymphocytes Sequentially Immunized <i>In Vivo</i> And <i>In Vitro</i> And Nonspecifically Expanded By Culture With Interleukin 2," <i>The Journal Of Immunology</i> 126(4):1318-1322, 1981.

EXAMINER

DATE CONSIDERED

3/

* EXAMINER:

Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.	
920010 535	

APPLICATION NO. 09/088,951

APPLICANTS

Martin A. Cheever and Mary L. Disis

		(Use several sheets if ne	cessary)	June 2, 1998	-	OUP ART UNIT				
,		······································	U.S.	PATENT DOCUMENTS						
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
			FOREI	GN PATENT DOCUMENTS						
		DOCUMENT NUMBER	DATE	COUNTRY	(TRANSLATION			
							YES NO			
				RT (Including Author, Title, Date, Pertiner R-2/neu Protein: A Target for A		rific Immun	otherany of			
Su	AA		-	es in Cancer Research 71:343-		ine miman	omerapy or			
	АВ			Cell and Antibody Immunity to acer Research 54:16-20, 1994.		Protein in I	Patients			
	AC		cers, John V	o the <i>HER</i> -2/neu oncogenic proviley & Sons, Chichester, 1994						
	AD	Disis et al., "Peptide-Based, but Not Whole Protein, Vaccines Elicit Immunity to HER 2/neu, an Oncogenic Self Protein," <i>The Journal of Immunology</i> 156:3151-3158, 1996.								
	AE		Disis et al., "Immunization with Homologous Foreign Proteins Generates Immunity Against "Self" Tumor Antigens," <i>The FASEB Journal Abstracts</i> 10(6):p. A1470, Abstra No. 2709, 1996.							
	Fisk et al., "Identification of an Immunodominant Peptide of HER-2/neu Protooncoger Recognized by Ovarian Tumor-specific Cytotoxic T Lymphocyte Lines," <i>J. Exp. Med.</i> 181:2109-2117, 1995.									
	AG			Gene MAGE-3 Codes for an Ar T Lymphocytes," <i>J. Exp. Med</i>			Melanoma			
	АН	1	_	stic Importance of c- <i>erb</i> B-2 Ex <i>logy 10</i> (7):1049-1056, 1992	xpression in	Breast Cano	cer,"			
	Al	Houghton, "Cancer Antigens: Immune Recognition of Self and Altered Self," J. Exp. Me 180:1-4, 1994.								
	AJ		Katsumata et al., "Prevention of breast tumor development <i>in vivo</i> by downregulation of the p185 ^{neu} receptor," <i>Nature Medicine 1</i> (7):644-648, 1995.							
	AK	Melanoma A	ntigen Reco	fication of the Immunodominal gnized by the Majority of HLA nal of Experimental Medicine	A-A2-restric 180:347-352	ted Tumor I				
EXAMINI		1 Cm		DATE CONSIDER	ED					
* EXAMIN				of this form with next communication to		h citation if not in				

FORM	PTO-1449
/DEV 7	90)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. 920010.535

APPLICATION NO. 09/088,951

APPLICANTS

Martin A. Cheever and Mary L. Disis

FILING DATE
June 2, 1998

GROUP ART UNIT 1642

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL Sur	AA	DO	Kern et al., "	p185 ^{neu} Exp	NAME ART (Including Author, Title, Date, Pertinent Paression in Human Lung Adenocal		SUBCLASS	FILING DATE
Su			Kern et al., "	p185 ^{neu} Exp				
gu 					ression in Human Lung Adenoca			
Su						cinomas P	redicts Sho	ortened
Su			Survivus, e.		arch 50:5184-5191, 1990.			100
	AB			,			•	
	АВ	L	Mahi-Brown	et al ."The	cellular immune response to imn	unization	with zona	nellucida
	AB				productive Immunology 21:29-46		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,
1	1	i i	antigens, 50	arnar of Re		,		
	-	-	Mamula et al	"Breaking	g T Cell Tolerance With Foreign-	And Self C	O-Immuno	gens. A
1	ا م				and T Cell Epitopes of Cytochro			
	AC				-195, 1992.			1
	-	-			to Process a Self-Peptide Allows	Autoreactiv	ve T Cells	to Escape
		1			. 177:567-571, 1993.	,		X.
	AD		Tolerance, a	. Exp. mea.	*			
	ļ	-	Matyas et al	"OncoVax	PTM vaccine for prostate cance	r induces in	nmune res	ponses to
					in prostate cancer patients," <i>Proc</i>			
	AE				Research Annual Meeting 40: 576			
	 	<u> </u>			e response to a differentiation anti			d antigen:
					on and autoimmunity," <i>Proc. Natio</i>			
	AF		14814, 1996	•		. 1400000 000	. 02.1.70	
-	 	-			luction of Anti-Self-Immunity to	Cure Cance	r." Cell 82	:13-17.
	AG		1995.	-				
	AU		1993.					
\		-	Peoples et al	"Breast ar	nd ovarian cancer-specific cytotox	ic T lymph	ocvtes rec	ognize the
	AH				l peptide," Proc. Natl. Acad. Sci. (
	An		Sumo HEIGH		, popolar, 1, 100, 1, 100, 100, 100, 100, 100, 1			
	1	\vdash	Schlichtholz	et al "The	Immune Response to p53 in Brea	st Cancer	Patients Is	Directed
. 1 .	AI				nt Epitopes Unrelated to the Muta			
	Ar .		Research 52:		÷ •			
	+	 			erization of antigenicity and immu	nogenicity	pattern of	native and
	AJ				cida proteins in the white-tailed de			
	^3				a and Fertility 101:295-303, 1994.		-	
		\vdash	Slamon et al	"Human F	Breast Cancer: Correlation of Rela	pse and Su	rvival with	1
	AK		Amplification	n of the HE	R-2/neu Oncogene," Science 235:	177-182.	1987.	
1	AK			,		· ·,		
	-	 	Takahashi et	al "Antibo	ody to ras Proteins in Patients with	1 Colon Ca	ncer," Clir	ical Cance
/ /	1		Research 1:1					
ψ	AL	1	Research 1.1	.0/1. 10//,				•
EXAMINI	ED	L			DATE CONSIDERED			
ZAZXIVIIINI	·		/ /		DATE CONSIDERED			

3/1/00

* EXAMINER:

Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO. 920010.535

APPLICATION NO. 09/088,951

APPLICANTS


Martin A. Cheever and Mary L. Disis

FILING	DA	TE
June	2.	1998

GROUP ART UNIT

Julic 2, 1998 1042													
				U.S.	PATENT	DOCUMENTS	,						
*EXAMINER INITIAL		DO	CUMENT NUMBER	DATE		NAME		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
	OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) Talmadge et al., "Preclinical evaluation of OncoVax-P a prostate cancer vaccine,"												
			Talmadge et a	al., "Preclin	ical evalu	ation of OncoVa	ax-P a pro	state can	cer vaccine	e,"			
C.	AA	l				ciation for Cand							
300			1996.			•				•			
:			Yonemura et	al "Evalua	tion of In	munoreactivity	for erB-2	2 Protein	as a Marke	r of Poor			
	AB					ancer," Cancer							
511	''		. 7			, , , , , , , , , , , , , , , , , , , ,							
m				\mathcal{F}_{i}	\$. 1)								
			•		,				**				
	AC			A STATE			• •						
en e	, AC		5	•					. *				
	AD					•							
	, AD		4		м.								
· · ·		1		· · · · · · · · · · · · · · · · · · ·									
	AE												
	AL			:	:								
<u> </u>		 			<u> </u>	*							
	AF					, ,							
	AF :												
* ****	<u> </u>	-					······································			· · · · · · · · · · · · · · · · · · ·			
	AG												
	AU	Ŷ						*					
· · · · · · · · · · · · · · · · · · ·													
	AH								•				
	АП		2 1										
8	-			· -									
	A 1												
	Al					•							
													
	AJ									·			
	AJ												
· · ·	,												
	A 12												
	AK		•										
				· · · · · · · · · · · · · · · · · · ·		·							
	AL												
EXAMINE	R	لــــا				DATE CONSI	DERED						
			1 /										
			0, 10	~		3/,	100						
* EXAMINI						conformance with MPE			itation if not in				
		confo	rmance and not concide	dered Include co	ny of this form	with next communica	tion to applica	ant/cl					





Sheet $\underline{1}$ of $\underline{1}$

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

SUPPLEMENTAL

ATTY. DOCKET NO. 920010.535

APPLICATION NO. 09/088,951

APPLICANTS

Martin A. Cheever and Mary L. Disis

INFORMATION DISCLOSURE STATEMENT									
		(Us	se several sheets if ne	cessary)		FILING DATE June 02, 1998		GROUP ART U	NIT
				U.S. 1	PATENT I	DOCUMENTS			
*EXAMINER INITIAL		DO	CUMENT NUMBER	DATE		NAME	CLA	SS SUBCL	ASS FILING DATE IF APPROPRIATE
	AA								
	,			FOREIC	GN PATEN	T DOCUMENTS	•		
		DO	CUMENT NUMBER	DATE		COUNTRY			TRANSLATION YES NO
	AB								
	1 12	l	ОТНЕ	R PRIOR AR	RT (Including	Author, Title, Date, Pertinent	Pages Fic)	
	AC					Present Lupus Auto			te Autoimmune
KAL	+					453-1461, 1994.	anti 5011.	Tilat IIIIIa	
	AD							-	
	AE								
	AF								
	AG								
	AH								
	AI								
	AJ								
	AK								
	AL								
	AM								
	AN				··-				
	AO								
EXAMINI	ER	<u> </u>	A Pa	0/4		DATE CONSIDERE	ED 7/	11/2	

EXAMINER	Jaren 1	1.	Ganella_	DATE CONSIDERED 3/24/03
* EXAMINER	Initial if refe	rence &	onsidered, whether or not criteria are in	conformance with MPEP 609. Draw line through citation if not in
l	conformance	and no	ot considered. Include copy of this form	with next communication to applicant(s).

MillicentS/339210

Date: 11/25/02